NeilDavidPalmisianoMDMS

Oncology • Philadelphia, PA

Hematologic Oncology

Associate Professor of Medical Oncology

Join to view full profile

Dr. Palmisiano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Palmisiano's full profile

Already have an account?

Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107
Phone+1 215-955-8874

Fax+1 215-955-2340

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2011 - 2014
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2008

Certifications & Licensure

NJ State Medical License 2018 - 2025
PA State Medical License 2008 - 2024
DE State Medical License 2018 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
Active, not recruiting
Phase 2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Start of enrollment: 2018 Aug 13
Recruiting
Phase 1, Phase 2
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Active, not recruiting
Phase 2
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Start of enrollment: 2020 Oct 16
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leuke...
Talha Badar, Ravi Narra, Alice S Mims, Michael G Heckman, Rory M Shallis
American Journal of Hematology. 2024-12-01
3 citations
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Mali...
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Emily C Craver
Haematologica. 2024-11-01
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results ...
Neil D Palmisiano, Ju-Whei Lee, David F Claxton, Elisabeth M Paietta, Hassan Alkhateeb
Ejhaem. 2024-10-01

Abstracts/Posters

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies
Neil Palmisiano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
Neil Palmisiano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Authored Content

IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy at SOHO 2021September 2021

Press Mentions

Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New JerseyOctober 3rd, 2022
ASH 2023: Tailoring Treatment in AMLDecember 22nd, 2023